βc (CSF2RB), is a shared receptor subunit for GM-CSF, IL-3, and IL-5, cytokines that drive the activation, survival, and recruitment of eosinophils, neutrophils, and macrophages. Trabikibart’s inhibition of βc simultaneously disrupts multiple pro-inflammatory pathways, offering a broad anti-inflammatory effect. This approach aims to reduce airway inflammation, exacerbations, and steroid dependence in respiratory diseases with mixed